Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Market capClose on Nov 9, 2026
- $1.49B
- Insider buysLast 90 days, $252.9K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +40 vs. previous quarter
- 104
- 13F valueReported value at the end of Q2 2026
- $1.67B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$209.8M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 5.15M
- Shares sold short
- Change
- +418.9K
- +8.9% vs. previous
- Days to cover
- 11.15
- At average daily volume
Superinvestors holding DMRA, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Damora Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.2%
Damora Therapeutics, Inc.'s share of the portfolio
- Shares
- 2,311,082
- Value
- $60.1M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Damora Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 28, 2026 (view filing)7:00 AM ET | Sep 25 | 3 days | Jarrett JenniferDirector, President and CEO | PPurchase | +12.5K | $20.23 | +$252.9K | +2.5%512.5K after | |
| Jul 7, 2026 (view filing)8:00 PM ET | Jul 6 | 1 day | Winslow GarrettGeneral Counsel | SSale | −245 | $29.98 | −$7.35K | −9.7%2.29K after | |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Schambye Hans T.Chief Executive Officer | SSale | −700 | $21.38 | −$15.0K | −13.0%4.68K after | |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Winslow GarrettGeneral Counsel | SSale | −255 | $21.38 | −$5.45K | −12.1%1.85K after | |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Firmani LoriChief Financial Officer | SSale | −135 | $21.41 | −$2.89K | −12.7%931 after | |
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Schambye Hans T.Chief Executive Officer | SSale | −735 | $3.38 | −$2.48K | −15.5%4.02K after | |
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Winslow GarrettGeneral Counsel | SSale | −260 | $3.39 | −$881.4 | −15.4%1.43K after | |
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Firmani LoriInterim CFO | SSale | −147 | $3.39 | −$498.33 | −17.5%692 after | |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Winslow GarrettGeneral Counsel | SSale | −471 | $5.60 | −$2.64K | −31.8%1.01K after | |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Firmani LoriInterim CFO | SSale | −261 | $5.63 | −$1.47K | −36.0%465 after |
Top 10 13F holders, Q2 2026
See all 104 holdersThe largest institutional positions in Damora Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 9,232,979 | $240.1M | 0.01% | +187,498+2.1% | Added |
| Fairmount Funds Management LLC | 8,713,000 | $226.6M | 14.98% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 3,783,000 | $98.4M | 0.88% | 00.0% | Unchanged |
| VR Adviser, LLC | 3,603,595 | $93.7M | 2.84% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,162,068 | $82.2M | 0.00% | +2,939,631+1,321.6% | Added |
| FCPM III Services B.V. | 2,441,000 | $63.5M | 8.46% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 2,399,702 | $62.4M | 0.54% | +3920.0% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 2,311,082 | $60.1M | 0.17% | 00.0% | Unchanged |
| Jupiter Topco LLC | 2,282,804 | $59.3M | 0.02% | +2,282,804 | New |
| Remedium Capital Partners, LLC | 2,045,473 | $53.2M | 11.78% | 00.0% | Unchanged |
Holders of 5% or more of DMRA
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Damora Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 13D/A | 19.99%8.71M shares | 0.00 ppfrom 19.99% | Nov 17, 20252 filings | Feb 11, 2026 | SEC |
| FMR LLC | 13G | 15.00%238.9K shares | New | Dec 5, 20251 filing | Dec 5, 2025 | SEC |
| Avoro Capital Advisors LLC | 13G | 6.27%3.78M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13G | 6.00%3.60M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.10%3.14M shares | New | Jul 28, 20261 filing | Jul 28, 2026 | SEC |